Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis

NCT06376968 | Recruiting

• 1 other identifier: BA-G-H-1604
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is: • Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires. A crossover design is used to compare treatments with or without the BioLogic Fusion function activated.

Conditions

Renal Dialysis

Outcome Measures

Primary Outcomes (1)

• Post-dialysis body weight

  percentage of sessions with reached prescribed post-dialysis body weight

  12 weeks

Study Arms (2)

BioLogic Fusion followed by standard dialysis

EXPERIMENTAL

Patients will be dialysed first with the BioLogic Fusion feature activated and then switched to standard dialysis with the BioLogic Fusion feature de-activated

Device: BioLogic Fusion

Standard dialysis followed by BioLogic Fusion

EXPERIMENTAL

Patients will be dialysed first with standard dialysis with the BioLogic Fusion feature de-activated and then switched to the BioLogic Fusion feature activated

Device: BioLogic Fusion

Interventions

BioLogic Fusion DEVICE

Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.

BioLogic Fusion followed by standard dialysis; Standard dialysis followed by BioLogic Fusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects ≥18 years of age
• Chronic bicarbonate standard high-flux haemodialysis or hemodiafiltration for at least 3 months
• Dialysis frequency 3 x per week
• Dialysis duration per session ≥ 4h
• Patient on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes
• No residual renal function (definition: ≤100 ml urine/day) - changed to "No to minimal residual renal function (definition: ≤ 300 ml/day)" with Amendment 1 (CIP version 6)
• Stable dry body weight for at least 4 weeks
• Subjects who are willing to give a voluntary consent to participate in the study

You may not qualify if:

• Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
• Vascular access insufficiency (mean blood flow \<200ml/min)
• Patients treated with dialysis profiles: sodium profile, Ultrafiltration (UF) profile, and temperature profile - changed to: " Patients treated with dialysis profiles during the 9 prescreening visits: sodium profile, UF profile, and temperature profile. However, patients on sodium, ultrafiltration or temperature profiling expected to reduce intradialytic hypotensive episodes can be evaluated for enrollment when their frequency of sessions complicated by hypotension demonstrate the lack of efficacy of the applied profiles" with Amendment 1 (CIP version 6)
• Use of the BioLogic fusion function during the last 9 dialysis sessions recorded at the site (retrospective screening period)
• Pregnant or nursing women. Women of childbearing potential must agree to avoid pregnancy during the study period
• Factors which may interfere with full participation in the trial
• Any contra-indication to haemodialysis treatment per se, as described in the Instructions for Use (IFU)
• Any serious medical condition or disability, which in the opinion of the investigator limits the life expectancy and would preclude completion of the study

Sponsors & Collaborators

• B.Braun Avitum AG: lead

Study Sites (1)

Policlinico S. Orsola - Malpighi - UOC Nefrologia, Dialisi e Ipertensione

Bologna, Emilia-Romagna, 40138, Italy

RECRUITING

Study Officials

• Annalisa Zucchelli, MD

  University Hospital Bologna

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Strube Frank

CONTACT

+4915257240618; frank.strube@bbraun.com

Seebode Christina, Dr.

CONTACT

christina.seebode@bbraun.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2024
• First Posted: April 22, 2024
• Study Start: April 22, 2024
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): June 1, 2027
• Last Updated: September 12, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)